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Commentary
An evaluation of the therapeutic potential
of fecal microbiota transplantation to
treat infectious and metabolic diseases
Albert K Groen1,2 & Max Nieuwdorp1,3,4
Fecal microbiota transplantation (FMT)
has had a long history in medicine for
treating a number of human diseases. As
early as during the 4th century BC, FMT
was used in China to treat patients with
food poisoning and diarrhea. Over time,
the method became obsolete, particularly
after the realization that hygiene plays an
important role in preventing infectious
diseases. It was not until the late 1950s
that FMT garnered interest again when
the first reports about its use to treat
fulminant enterocolitis appeared in the
scientific literature. However, FMT's
breakthrough as the method of choice for
the treatment of persistent Clostridium
difficile infection (CDI) came only after a
double-blind randomized trial (van Nood
et al, 2013), which demonstrated 94% effi-
cacy of FMT compared with 31% after
conservative treatment with vancomycin.
F MT as a treatment modality has alsobeen tested in a range of otherdiseases, such as inflammatory bowel
disease (IBD), irritable bowel syndrome,
obesity and metabolic syndrome, as well as
neurological and psychological disorders,
although most reports of the latter category
are merely anecdotal. Yet, the results so far
are not convincing. Reports about using
FMT to treat IBD patients show considerable
heterogeneity in terms of clinical effect
(Moayyedi et al, 2015), whereas efficacy in
patients with metabolic syndrome was tran-
sient. Insulin resistance improved 6 weeks
after the FMT, but at 12 weeks, no
significant effect was observed anymore on
metabolic parameters and fecal microbiota
composition (Vrieze et al, 2012).
The reason why FMT has such variable
efficacy is probably due to the stability and
resilience of the gut microbiota. CDI patients
who have been treated multiple times with
antibiotics have most of their bacterial diver-
sity wiped out; FMT effectively repopulates
this vacated space with a stable and healthy
bacterial community (Girotra et al, 2016). In
contrast, FMT recipients with metabolic
syndrome were obese but otherwise healthy
individuals with a stable and diverse fecal
microbiota. Further investigation of why
FMT failed to engraft novel species or
change the gut microbiota in these naı¨ve
patients confirmed that their bacterial
community is largely resilient to accepting
new members in their midst. This “gated
community” makes exceptions only for
donor strains that are closely related—as
identified via single nucleotide variants—to
species that are already present in the
patient’s intestine (Li et al, 2016).
The regulatory factors that control a
person’s fecal microbial composition are not
understood yet. A recent study addressed
the important question of who sits at the
gatehouse of the gut microbial community:
the bacteria themselves, the host or both?
Using a novel procedure called dissimilarity
overlap curves (DOC), the authors looked at
general relationships and cross-talk between
bacterial species independent of the host,
which should predict the relative proportion
of that species in the microbial community
(Bashan et al, 2016). They indeed observed
host-independent cross-talk, suggesting that
the influence of the host, at least on the
distribution of the major species, may be
rather small. This conclusion also challenges
any notion that the host immune system
plays an important role in controlling the
microbial community. Clearly, the study by
Bashan and colleagues requires validation
because of the potentially major conse-
quences for engraftment with fecal micro-
biome-based probiotics. If the influence of
the host can really be ignored, it should be
possible to develop generic procedures and
products to manipulate microbiota composi-
tion, which would simplify probiotic therapy
enormously.
Another explanation for the differences in
the efficacy of FMT to treat various diseases
is the tremendous variation in experimental
protocols. Feces are prepared by different
methods: dilution in saline, milk, water, or
glycerol; different exposure time to the toxic
oxygen environment; and varying modes of
application all cause inconsistency. All these
differences make it impossible to compare
the results of different studies. Standard
operation procedures for FMT are therefore
urgently needed. Even when using standard-
ized procedures, there is still the variable
composition of donor and recipient micro-
biota that has to be dealt with. Donor health
status will have to be screened extensively.
Efficacy of frozen stool has been compared
to fresh material in studies with CDI patients
and no significant difference was observed
(Lee et al, 2016), which provides the
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opportunity to characterize donor feces prior
to application.
Moreover, in most studies published so
far, the effects of FMT on human physiology
were associated with bacterial composition.
However, depending on the pre-purification
procedure, human feces contain consider-
ably more than just bacteria. With the intro-
duction of metagenomic analysis, it has
become clear that, in addition to bacteria,
the fecal microbiota contains a considerable
amount of viruses, fungi, and phages as well
as intact shedded colonocytes. A recent
study reported that feces contained 1011
bacteria/g, 107 intact colonocytes/g, 108
viruses/g and 108 archae/g. Although bacte-
ria clearly dominate the gut population, it
cannot be excluded that other components
such as viruses and miRNAs influence host
physiology (Liu et al, 2016).
To our knowledge, there have been no
well-documented serious adverse events
after FMT reported since its rejuvenation in
1958. However, the lack of randomized,
well-controlled, and well-documented stud-
ies does not exclude that such events have
occurred. At the Academic Medical Center in
Amsterdam, 600 FMTs have been carried
out, mostly as research projects, and no
adverse events have occurred so far. Given
all the available data, we can conclude that
FMT is a safe procedure. Nevertheless, a
more optimal and safer way would either use
standardized capsules from well-screened
donors feces (Youngster et al, 2014), or
encapsulated well-characterized mixtures of
cultured microorganisms that have been
proven to cure human disease. Unfortu-
nately, this ideal situation is still far away
from therapeutic application. As of now, no
single bacterial strain or microorganism has
been shown to be able to significantly impact
human health. Interestingly, a combination
of several novel probiotic bacterial strains
has been shown to successfully treat patients
with CDI, suggesting that this may be way to
go (Khanna et al, 2016).
We speculate that improved delivery—
for instance, by pH-driven release from oral
capsules—and more adequate oral dosing,
which is currently limited to 1012 CFU/day
orally, of these novel probiotic strains might
improve engraftment and efficacy. However,
as previously mentioned, the residing gut
microbial community is resilient to changes
induced from the outside. Most probably,
this could be overcome by sustained applica-
tion of higher doses of a beneficial bacteria
mixture or pretreatment with antibiotics.
Future studies will have to ascertain
whether these hypotheses hold true.
In addition, diet considerably influences
fecal microbiota composition. Switching
from a diet of animal-derived products to
one composed of plant-derived products
induces significant functional changes in
microbiota composition. These changes are
directly linked to, for instance, the type of
fiber that has to be degraded, suggesting that
substrate availability is a strong regulating
factor in microbial composition and thus
might be instrumental in engraftment of
donor bacterial strains. Selecting the right
diet for beneficial bacteria may pave the
way for a more successful use of FMT.
In conclusion, further ongoing human
research using FMTs will hopefully help to
identify single or combination of bacterial
strains that can be used as diagnostics or
therapeutics. Moreover, these studies will
show if fecal microbiota are indeed drivers
of disease instead of being merely disease
modifiers (Bonder et al, 2016). Other clinical
factors that have not been addressed in
these studies, such as ethnicity, are currently
investigated in the AMC HELIUS study along
with prospective follow-up of participants
(Stronks et al, 2013). Nevertheless, all of
these identified bacterial strains should be
repetitively identified in other cohorts
comprising patients with the same disease.
Also, there should be correlations with other
biomarkers (e.g. like HbA1c) and these
bacterial strains should prospectively be
linked to disease outcome (such as develop-
ment of de novo type 2 diabetes) in epidemi-
ological studies (Fig 1). Only when these
three criteria are fulfilled, it is expected that
we can predict disease development in
humans based on their microbiota and can
be treated accordingly.
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Figure 1. Schematic overview of identifying diagnostic and therapeutic bacterial strains from FMT.
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